Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Eppendorf North America and the journal Science are now accepting applications for the 2013 Eppendorf and Science Prize for Neurobiology—an annual international research prize of $25,000. The prize is awarded to one young scientist for his or her outstanding contributions to neurobiology research. Researchers 35 years old or younger are invited to apply by June 15.
Roche and Hamilton Robotics have introduced an integrated platform that enables automated DNA sample enrichment for Roche’s 454 GS Junior sequencer. The platform builds on the integration of Roche’s REM e system with Hamilton’s Microlab Nimbus NGS workstation, resulting in reduced hands-on time, minimized operational variability, and more consistent results.
Evogen has entered into a nonexclusive license agreement with Focus Diagnostics granting worldwide rights to incorporate Evogen HyBeacons PCR probe technology into Focus Diagnostics’ molecular diagnostic products and services.
SciGene Corp.’s Hyb-Ice thermal profiling system performs everyday temperature profiles. The system consists of a programmable heating/cooling base and removable block that heat and cool samples from 4° to 99°C. It accommodates a variety of quick-change blocks to fit nearly any tube or plate.
Quality Laboratory Solutions has added to its LinChek product line of calibration verification/linearity material a chemistry linearity test set. The new test set is a liquid product packaged as six distinct levels with three ampules of 1 mL for each level. Twenty-five different analytes, including the most-requested tests, are included. An 18-month supply of product is available with each test set by providing three separate sets of linearity material.
Hamilton Robotics announced that the CytoScan automated target preparation solution from Affymetrix is built on Hamilton’s customizable Microlab Nimbus 96 workstation. The Nimbus 96 instrument automates target preparation for the CytoScan cytogenetics solution, which offers broad coverage for detecting human chromosomal aberrations.
Streck’s CVA, an assayed linearity control kit used to determine the patient reportable range of three- and five-part hematology instruments, is now assayed for Beckman Coulter’s UniCel DxH 800. CVA establishes an instrument’s reportable range and verifies linearity, testing the instrument’s extreme upper and lower limits, ensuring that patient results are valid.
Nanosphere has obtained the CE-IVD Mark for its gram-negative blood culture test (BC-GN) on the automated sample-to-result Verigene system. The test expands Nanosphere’s infectious disease test capabilities to include rapid detection of bacteria that can cause deadly bloodstream infections.
Oncomatrix’s DMTXinvaScan is an immunohistochemistry-based kit designed to diagnose and predict the invasiveness of pancreas, breast, lung, colon, and head and neck tumors. The main component of DMTXinva-Scan is a monoclonal antibody that detects collagen XI-α1. Oncomatrix developed and clinically validated this antibody.
Biosearch Technologies has acquired exclusive worldwide rights to continuing Stellaris RNA FISH-based inventions from the University of Medicine and Dentistry of New Jersey. In addition to single-molecule detection of mRNA, lncRNA, and viral RNAs, Stellaris-based methods have been extended to directly and quantitatively detect chromosomal diseases caused by translocations and aberrant splice junctions and single-nucleotide polymorphisms.
